Tiger Brokers

BUZZ-Krystal Biotech falls on Q1 results miss

Reuters
May 06
BUZZ-Krystal Biotech falls on Q1 results miss 

** Shares of drugmaker Krystal Biotech KRYS.O fall 9.8% to $146.4

** KRYS posts Q1 revenue of $88.2 million, missing analysts' average estimate of $96.24 million, according to data compiled by LSEG

** Co reports Q1 adj. profit of $1.20/share vs analysts' estimate of $1.37/share

** Krystal Biotech has one approved drug on the market, Vyjuvek, a gene therapy used to treat dystrophic epidermolysis bullosa (DEB), a rare genetic skin condition

** Patients with the condition suffer from open wounds, causing skin infections, and are at an increased risk of vision loss, scarring and skin cancer

** As of last close, KRYS stock up 3.6% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10